Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Night-shift-related Migraine in Healthcare Professionals
NCT07918053Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of rimegepant in migraine (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Mean number of moderate-to-severe migraine days per evaluable night-shift-related observation window at 8 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07918053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918053.